NCT06142396View on ClinicalTrials.gov

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2027

Conditions
Multiple MyelomaRenal Failure
Interventions
COMBINATION_PRODUCT

Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone

"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."

Trial Locations (1)

30912

RECRUITING

Georgia Cancer Center-Augusta University, Augusta

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Augusta University

OTHER